# Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

> **NCT01736917** · PHASE2 · COMPLETED · sponsor: **Lawrence Einhorn** · enrollment: 65 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting

## Interventions

- **DRUG:** Fosaprepitant
- **DRUG:** Dexamethasone
- **DRUG:** 5HT3

## Key facts

- **NCT ID:** NCT01736917
- **Lead sponsor:** Lawrence Einhorn
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-06
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2016-05-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01736917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01736917, "Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01736917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*